Sunday 18 October 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million. In the quarter to June 2026, EPS grew 35.5% and free cash flow grew 26.7%, each against the same quarter a year earlier.
7.02
0.88
−11.14%
Follow CTNM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (28.01%) | (26.88%) | (26.13%) | (30.40%) |
+8 more TTM periods Free account |
|
| (26.57%) | (25.43%) | (24.51%) | (29.19%) | ||
ROIC |
(1,334.41%) | (1,125.32%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(24.29%) | (23.63%) | (23.16%) | (33.09%) | |
Free Cash Flow per Share |
(1.43) | (1.54) | (2.01) | (1.88) | |
Free Cash Flow |
(53.46) | (57.66) | (55.54) | (52.83) | |
Capital Expenditures |
(0.46) | (0.50) | (0.23) | (0.35) | |
| Other line items | |||||
Cash ROIC |
(11.23%) | (11.62%) | (10.60%) | (14.56%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 0.98 | 0.92 | 0.88 | |
Depreciation/Fixed assets |
0.41 | 0.31 | 0.39 | 0.36 | |
Capex/Depreciation |
(1.20) | (1.51) | (0.72) | (1.13) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.41) | (1.53) | (2.00) | (1.87) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates